摘要 Clinical benign prostatic hyperplasia (BPH) is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms (LUTS). The prevalence of BPH increases after the age of 40 years, with a prevalence of 8%-60% at age 90 years. Some data have suggested that there is decreased risk among the Asians compared to the western white population. Genetics, diet and life style may play a role here. Recent reports suggest the strong relationship of clinical BPH with metabolic syndrome and erectile dysfunction, as well as the possible role of inflammation as a cause of the prostatic hyperplasia. Lifestyle changes including exercise and diet are important strategies in controlling this common ailment.
Abstract: Clinical benign prostatic hyperplasia (BPH) is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms (LUTS). The prevalence of BPH increases after the age of 40 years, with a prevalence of 8%-60% at age 90 years. Some data have suggested that there is decreased risk among the Asians compared to the western white population. Genetics, diet and life style may play a role here. Recent reports suggest the strong relationship of clinical BPH with metabolic syndrome and erectile dysfunction, as well as the possible role of inflammation as a cause of the prostatic hyperplasia. Lifestyle changes including exercise and diet are important strategies in controlling this common ailment.
作者简介: Kok Bin Lim,E-mail address:lim_kokbin@rafflesmedical.com.
引用本文:
Kok Bin Lim. Epidemiology of clinical benign prostatic hyperplasia[J]. Asian Journal of Urology, 2017, 4(3): 148-151.
Kok Bin Lim. Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 2017, 4(3): 148-151.
[1] Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9. [2] Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990;17:241-6. [3] Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men:the Krimpen Study. J Urol 2009;181:710-6. [4] Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men:the MrOS study. Urology 2006;68:804-9. [5] Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study:prediction of future prostate volume in individual men. Prostate 2007;67:1816-24. [6] Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time:results from the Baltimore Longitudinal Study of Aging. J Urol 2009;182:1458-62. [7] Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM. The longterm relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men:the Krimpen study. Eur Urol 2008;53:819-27. [8] Fowler Jr JE, Bigler SA, Kilambi NK, Land SA. Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology 1999;53:1175-8. [9] Kaplan SA, Reis RB, Staimen VB, Te AE. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts? Br J Urol 1998;82:804-7. [10] Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study. J Urol 2000;163:490-5. [11] Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994;152:115-9. [12] Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 1997;157:876-9. [13] Pearson JD, Lei HH, Beaty TH, Wiley KE, Isaacs SD, Isaacs WB, et al. Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 2003;61:781-5. [14] Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms:new approaches to old problems. J Urol 2007;178:395-401. [15] Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia:results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008; 167:925-34. [16] Tavani A, Longoni E, Bosetti C, Maso LD, Polesel J, Montella M, et al. Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia:a case-control study from Italy. Eur Urol 2006;50:549-54. [17] Fowke JH, Phillips S, Koyama T, Byerly S, Concepcion R, Motley SS, et al. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int 2013;111:122-8. [18] Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community dwelling men. BJU Int 2008;101:313-8. [19] Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol 2009; 182:1463-8. [20] Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-8. [21] Joseph MA, Wei JT, Harlow SD, Cooney KA, Dunn RL, Jaffe CA, et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate 2002;53:322-9. [22] Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia:clinical connections, emerging etiological paradigms and future directions. J Urol 2009;182(Suppl. 6):S27-31. [23] Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men:the osteoporotic fractures in men study. Eur Urol 2011;60:1173-80. [24] Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia:results from the prostate cancer prevention trial. J Urol 2007;177:1395-400. quiz 1591. [25] Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptomsewhat do we know? J Urol 2009;182(Suppl. 6):S32-7. [26] Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia:a prospective cohort study of air force veterans. Urology 2006; 68:1198-205. [27] Rosen RC, Link CL, O'Leary MP, Giuliano F, Aiyer LP, Mollon P. Lower urinary tract symptoms and sexual health:the role of gender, lifestyle and medical comorbidities. BJU Int 2009; 103(Suppl. 3):42-7. [28] Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction:co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur Urol 2003;44:588-94. [29] Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004;64:772-6. [30] El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction:analysis of risk factors. J Sex Med 2006; 3:144-9. [31] McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-45. [32] Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-81. [33] Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia:a retrospective analysis. Eur Urol 2003;43:164-75. [34] Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia:results from the prostate cancer prevention trial. Am J Epidemiol 2010;171:571-82. [35] St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal anti inflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006;164:760-8. [36] St Sauver JL, Jacobsen SJ, Jacobson DJ, McGree ME, Girman CJ, Nehra A, et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 2011;107:443-50. [37] Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, et al. Indications for and use of nonsteroidal anti inflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia:results from the prostate cancer prevention trial. Am J Epidemiol 2012;176:156-63. [38] Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, et al. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int 2012;110:1050-9. [39] Choi WS, Lee WK, Lee SH, Lee SK, Cho ST, Kim DH. Is highsensitivity C-reactive protein associated with lower urinary tract symptoms in aging men? Results from the hallym aging study. Korean J Urol 2012;53:335-41. [40] Chang IH, Oh SY, Kim SC. A possible relationship between testosterone and lower urinary tract symptoms in men. J Urol 2009;182:215-20.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
